Brind.
  1. A combined team of Biodexa Pharmaceuticals, Emtora Biosciences, LumaBridge, Precision for Medicine, and Pfizer is advancing eRapa for FAP treatment.

Biodexa, Emtora, and LumaBridge formed a collaboration to advance the Serenta trial, with the Cancer Prevention and Research Institute of Texas hosting the work.

3 reports, 1 independent Updated Aug 19
Gone quiet
Reports
3
Developments
1
Repetition
67%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Biodexa, Emtora, and LumaBridge formed a collaboration to advance the Serenta trial, with the Cancer Prevention and Research Institute of Texas hosting the work.

Who's involved

What this event is mainly about
Cancer Prevention and Research Institute of Texas

Keep exploring

Part of

A combined team of Biodexa Pharmaceuticals, Emtora Biosciences, LumaBridge, Precision for Medicine, and Pfizer is advancing eRapa for FAP treatment. All 1 developments

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireBiodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Pha
  • Unknown outlet
1 more outlet ran the same wire story